Concepedia

Publication | Open Access

Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab

DOIFull Paper Access

59

Citations

18

References

2019

Year

Justin Moser, Danli Chen, Siwen Hu‐Lieskovan, Kenneth F. Grossmann, Shiven B. Patel, Sarah V. Colonna, Jian Ying, John Hyngstrom
Cancer Medicine

Abstract

In our real-world retrospective analysis, patients with advanced BRAF mutant melanoma treated with front-line niv/ipi or aPD-1 had longer survival compared to those treated with front-line BRAF/MEKi.

References

YearCitations

Page 1